SMS Pharmaceuticals Limited
Valuation (67/100) does the heavy lifting; momentum (44/100) is the drag.
Buy zoneOur blended model reads SMS Pharmaceuticals Limited as a Buy at 60/100. We put fair value near ₹421.39; at ₹373.9 that leaves roughly 13% upside, so the stock screens fairly valued. On 34.2x trailing earnings it sits roughly in line with the Healthcare median of about 37.6x. The price is about 15% below its 52-week high of ₹438.3 and 74% above the low of ₹214.42. Financial health scores 84/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. It clears 7 of 13 investability checks, with durability 60, valuation 62 and momentum 44 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹337.11.
1-year price
EOD · 2026-07-3152-week range
-14.69% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy60Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 14.3%
- Pass: Low debt (D/E < 0.5): 0.46x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: -4%
- Pass: Earnings growing: 49%
- Pass: Net margin ≥ 10%: 11.5%
- Pass: Current ratio > 1.5: 1.81
- Pass: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 4.36
- Fail: Piotroski ≥ 7: 5/9
Shareholding
- Promoter76.5%
- Institutions2.8%
- Public & other20.6%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Financially solid — Altman Z 4.36.
Opportunities
- Earnings growing (49% YoY).
- Trading in our value buy zone versus sector peers.
About SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients and intermediates globally. Its product portfolio spans anti-retroviral, anti-inflammatory, anti-viral, anti-diabetic, anti-fungal, anti-epileptic, anti-migraine, anti-coagulant, anti-psychotic, anti-anginal, and anti-ulcer categories. The company also conducts contract research on peptides.
SMS Pharmaceuticals Limited — frequently asked questions
Is SMS Pharmaceuticals Limited a buy, hold or sell?
StocksWizard currently rates SMS Pharmaceuticals Limited (SMSPHARMA) a Buy, based on a blended score of 60/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is SMS Pharmaceuticals Limited's fair value?
Our blended DCF and relative-valuation model estimates SMS Pharmaceuticals Limited's fair value at about ₹421.39, versus a current price of ₹373.9 — roughly 13% upside. On that basis the stock looks fairly valued.
Is SMS Pharmaceuticals Limited financially healthy?
SMS Pharmaceuticals Limited scores 84/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has SMS Pharmaceuticals Limited's share price performed?
SMS Pharmaceuticals Limited is down 7% over three months, and last traded at ₹373.9. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.